Prof. Rafael Beyar
Co-Founder and Managing General Partner @ ALIVE Israel HealthTech Fund
Haifa, Israel
Prof. Rafael Beyar is a Series A investor at ALIVE Israel HealthTech Fund in Haifa focused on Medical Device and Medical. Prof. Rafael Beyar
- Total investments:
- 4
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Prof. Rafael Beyar invests in
Stages Prof. Rafael Beyar invests in
Countries Prof. Rafael Beyar invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Series A
- $1M–$17M
Investment Focus
Industry
- Medical Device 3 (75%)
- Medical 1 (25%)
- mHealth 1 (25%)
- Software 1 (25%)
- Health Care 1 (25%)
Stage
- Series A 2 (50%)
- Seed 1 (25%)
- Series B 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| UltraSight aims to revolutionize ultrasound through the power of machine learning to enable more accurate and timely clinical decisions. The UltraSight automated guidance system helps bring the benefits of cardiac imaging to healthcare professionals in new care settings, allowing patients access to ultrasound anywhere. UltraSight won the TCT 2020Innovation Competition which took place during the Transcatheter Cardiovascular Therapeutics world conference. For mor information please visit us at www.ultrasight.com | $24M / Series B / Sep 23, 2026 | ||
| Vessi Medical, an Israeli medical device startup, brings a new approach to treat Non-Muscle-Invasive Bladder Cancer (NMIBC). Vessi uses surface cryotherapy, a treatment that utilizes extreme cold, to freeze and destroy abnormal tissue.Categorized as surface cancer on the inside lining of the bladder, NMIBC affects 2 million people globally with300,000 new cases reported every year. TransUrethral Resection of Bladder Tumor (TURBT) is the leading first-line therapy. Yet, this invasive surgical procedure, requiring a costly hospital stay performed under general anesthesia, can often be inadequate. In up to 80% of cases the cancer returns, with increased complications as patients need multiple repeat procedures that further reduce quality of life.Vessi's minimally invasive NMIBC solution provides a new, first-line, office-based therapy alternative to surgery. The company's patent-pending, bladder-specific cryotherapy technology eliminates costly and problematic repeat surgeries seen with TURBT, reducing the need for hospital stay by providing in office or ambulatory treatment. The technology successfully ablates unwanted tissue, reduces the risk of dispersed cancers cells, all while causing no bladder damage. The Vessi system consists of a standalone console and a disposable catheter that is inserted into the bladder. Vessi is backed by the Trendlines Group, a leading Israeli early stage investor, and led by seasoned medical device and cryotherapy veterans. The company has already demonstrated promising proof of concept in animals with its Alpha product. Vessi’s first application will initially target the $1.2 billion NMIBC market, with future applications for the treatment of overactive bladder and urinary tract infections, both billion-dollar markets. | $16.5M / Series A / Feb 14, 2024 | ||
| MedHub-AI develops deep-learning video analysis algorithms that provide accurate diagnostic insights and practical guidance for physicians. Users can incorporate its algorithm into medical video systems to improve the decision-making process for cardiologists and other physicians. Its technology uses multiple technological and big-data processingmethods designed to handle a massive amount of clinical data, both visual and textual. It designs its algorithms to improve physicians' performance and shorten procedure times by providing a multilayered automated system that is implemented from diagnosis to practical procedural guidance and documentation. It currently offers solutions for the cardiology and gastroenterology markets. | $1M / Series A / Dec 15, 2021 | ||
| MedHub-AI develops deep-learning video analysis algorithms that provide accurate diagnostic insights and practical guidance for physicians. Users can incorporate its algorithm into medical video systems to improve the decision-making process for cardiologists and other physicians. Its technology uses multiple technological and big-data processingmethods designed to handle a massive amount of clinical data, both visual and textual. It designs its algorithms to improve physicians' performance and shorten procedure times by providing a multilayered automated system that is implemented from diagnosis to practical procedural guidance and documentation. It currently offers solutions for the cardiology and gastroenterology markets. | Seed / Dec 05, 2021 |
Co-Investors
ALIVE Israel HealthTech Fund is a pioneer mid-to-late stage HealthTech fund leveraging an exclusive ecosystem.
ALIVE Israel HealthTech Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Ari Shamiss
Co-Founder and Managing General Partner
|
|||
Dudi Klein
Co-Founder and Managing Partner
|
|||
Dudi Klein
Co-Founder and Managing Partner
|
|||
Michel Habib
Co-Founder & Managing General Partner
|
|||
|
Prof. Rafael Beyar
Co-Founder and Managing General Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Prof. Rafael Beyar invest in?
Prof. Rafael Beyar invests primarily in Medical Device, Medical and mHealth startups, most often at Series A and Seed stage. Most of the 4 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Prof. Rafael Beyar invest in?
Prof. Rafael Beyar typically joins rounds of $1M–$17M at Series A. These are whole funding-round sizes, not Prof. Rafael Beyar's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Prof. Rafael Beyar took part in.
How do I contact Prof. Rafael Beyar?
Public channels for Prof. Rafael Beyar include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Prof. Rafael Beyar last invest?
The most recent investment recorded for Prof. Rafael Beyar closed in Sep 2026. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
